Visual analysis of fatigue in Industry 4.0

The performance of manufacturing operations relies heavily on the operators’ performance. When operators begin to exhibit signs of fatigue, both their individual performance and the overall performance of the manufacturing plant tend to decline. This research presents a methodology for analyzing fatigue in assembly operations, considering indicators such as the EAR (Eye Aspect Ratio) indicator, operator pose, and elapsed operating time. To facilitate the analysis, a dataset of assembly operations was generated and recorded from three different perspectives: frontal, lateral, and top views. The top view enables the analysis of the operator’s face and posture to identify hand positions. By labeling the actions in our dataset, we train a deep learning system to recognize the sequence of operator actions required to complete the operation. Additionally, we propose a model for determining the level of fatigue by processing multimodal information acquired from various sources, including eye blink rate, operator pose, and task duration during assembly operations.Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. “A way of making Europe” European Regional Development Fund (ERDF) and MCIN/AEI/10.13039/501100011033 for supporting this work under the MoDeaAS project (grant PID2019-104818RB-I00)

Anomaly detection and virtual reality visualisation in supercomputers

Anomaly detection is the identification of events or observations that deviate from the expected behaviour of a given set of data. Its main application is the prediction of possible technical failures. In particular, anomaly detection on supercomputers is a difficult problem to solve due to the large scale of the systems and the large number of components. Most research works in this field employ machine learning methods and regression models in a supervised fashion, which implies the need for a large amount of labelled data to train such systems. This work proposes the use of autoencoder models, allowing the problem to be approached with semi-supervised learning techniques. Two different model training approaches are compared. The former is a model trained with data from all the nodes of a supercomputer. In the latter approach, observing significant differences between nodes, one model is trained for each node. The results are analysed by evaluating the positive and negative aspects of each approach. On the other hand, a replica of the Marconi 100 supercomputer is developed in a virtual reality environment that allows the data from each node to be visualised at the same time.Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. We would like to thank “A way of making Europe” European Regional Development Fund (ERDF) and MCIN/AEI/10.13039/501100011033 for supporting this work under the MoDeaAS project (grant PID2019-104818RB-I00). Furthermore, we would like to thank the University of Skövde and to ASSAR Innovation Arena for their support to develop this work

Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials

Migraine; PreventionMigranya; PrevencióMigraña; PrevenciónBackground Several novel treatments targeting the calcitonin gene-related peptide pathway have been developed for migraine. We evaluated the efficacy of these medications, including atogepant, rimegepant, erenumab, eptinezumab, fremanezumab, and galcanezumab, for the prevention of migraine via network meta-analysis. Methods Databases, including MEDLINE via PubMed, EMBASE, and Cochrane central, were systematically reviewed, and all eligible phase 3 randomised controlled trials were included. Results Nineteen studies (n = 14,584 participants) were included. Studies included episodic (n = 11) and chronic (n = 4) migraine or both (n = 4). All interventions, except for eptinzumab 30 mg, significantly reduced mean monthly migraine days compared to placebo. All medications had a higher ≥50% responder rate than placebo and results were statistically significant in those with the subcutaneous or intravenous route of administrations, but not with the oral one. All medications significantly reduced mean monthly headache days, although no data for this outcome was available for rimegepant, and mean monthly acute medication days, with no data for eptinezumab. Conclusion The results show that medications targeting calcitonin gene-related peptide were effective in preventing migraine compared to placebo. Considering limitations of single studies, different populations such as episodic and chronic migraine, and the absence of head-to-head trials, all novel treatments decreased mean monthly migraine and headache days, and showed higher 50%, 75% and 100% responder rates than placebo

Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review

COVID-19; Telemedicine; VaccineCOVID-19; Telemedicina; VacunaCOVID-19; Telemedicina; VacunaObjective The objective is to summarize the knowledge on the epidemiology, pathophysiology and management of secondary headache attributed to SARS-CoV-2 infection and vaccination; as well as to delineate their impact on primary headache disorders. Methods This is a narrative review of the literature regarding primary and secondary headache disorders in the setting of COVID-19 pandemic. We conducted a literature search in 2022 on PubMed, with the keywords “COVID 19” or “vaccine” and “headache” to assess the appropriateness of all published articles for their inclusion in the review. Results Headache is a common and sometimes difficult-to-treat symptom of both the acute and post-acute phase of SARS-CoV-2 infection. Different pathophysiological mechanisms may be involved, with the trigeminovascular system as a plausible target. Specific evidence-based effective therapeutic options are lacking at present. Headache attributed to SARS-CoV-2 vaccinations is also common, its pathophysiology being unclear. People with primary headache disorders experience headache in the acute phase of COVID-19 and after vaccination more commonly than the general population. Pandemic measures, forcing lifestyle changes, seemed to have had a positive impact on migraine, and changes in headache care (telemedicine) have been effectively introduced. Conclusions The ongoing COVID-19 pandemic is a global challenge, having an impact on the development of secondary headaches, both in people with or without primary headaches. This has created opportunities to better understand and treat headache and to potentiate strategies to manage patients and ensure care

¿Qué preguntar, cómo explorar y qué escalas usar en el paciente con cefalea? Recomendaciones del Grupo de Estudio de Cefalea de la Sociedad Española de Neurología

Cefalea; Anamnesis; ExploraciónCefalea; Anamnesi; ExploracióHeadache; Anamnesis; ExplorationIntroduction Headache is the most common neurological complaint at the different levels of the healthcare system, and clinical history and physical examination are essential in the diagnosis and treatment of these patients. With the objective of unifying the care given to patients with headache, the Spanish Society of Neurology’s Headache Study Group (GECSEN) has decided to establish a series of consensus recommendations to improve and guarantee adequate care in primary care, emergency services, and neurology departments. Methods With the aim of creating a practical document, the recommendations follow the dynamics of a medical consultation: clinical history, physical examination, and scales quantifying headache impact and disability. In addition, we provide recommendations for follow-up and managing patients’ expectations of the treatment. Conclusions With this tool, we aim to improve the care given to patients with headache in order to guarantee adequate, homogeneous care across Spain.Introducción La cefalea es el motivo de consulta neurológico más prevalente en los distintos niveles asistenciales, donde la anamnesis y exploración son primordiales para realizar un diagnóstico y tratamiento adecuados. Con la intención de unificar la atención de esta patología, el Grupo de Estudio de Cefalea de la Sociedad Española de Neurología (GECSEN) ha decidido elaborar unas recomendaciones consensuadas para mejorar y garantizar una adecuada asistencia en Atención Primaria, Urgencias y Neurología. Metodología El documento es práctico, sigue el orden de la dinámica de actuación durante una consulta: anamnesis, escalas que cuantifican el impacto y la discapacidad y exploración. Además, finaliza con pautas para realizar un seguimiento adecuado y un manejo de las expectativas del paciente con el tratamiento pautado. Conclusiones Esperamos ofrecer una herramienta que mejore la atención al paciente con cefalea para garantizar una asistencia adecuada y homogénea a nivel nacional

Neurology training and research in the Covid-19 pandemic: A survey of the Resident and Research Fellow Section of the European Academy of Neurology.

INTRODUCTION The COVID-19 (SARS-CoV2) outbreak has disrupted residency programs due to the university and hospital's priorities to face this emergency at all expenses. Most research projects and clinical trials were temporarily stopped or postponed. The Resident and Research Fellow Section (RRFS) of the European Academy of Neurology (EAN) has decided to assess the impact of the COVID-19 pandemic on neurology training. METHODS All EAN RRFS members were invited to fill out an online questionnaire of 40 items concerning their clinical involvement during the COVID-19 emergency, and the impact of the pandemic on their training. RESULTS Of the 227 RRFS members who completed the questionnaire, 222 were from Europe, and from those 111 were from Portugal, Italy or France. Responders highlighted that severe restrictions have been amended to face this pandemic, including reduction of inpatient beds, prohibition of in-person visits and limitation to hospitals access for patients' relatives. This was accompanied by an increase in email correspondence and phone calls with 50 % of countries allowing telemedicine to reach outpatients. Seventy-nine percent of the respondents felt that the pandemic will likely have a serious impact on their training and career. CONCLUSION The pandemic lead to a disruption of neurology activities, including medical training and research. The long-run impact of these changes remains unknown, but it will likely change the way neurology practice and training will be organized for future generations

Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination

Safety and efficacy of vaccines against the SARS-CoV-2 coronavirus has been demonstrated in clinical trials and next by their real world use through the course of the ongoing COVID-19 pandemic. However, very rare adverse events have been detected post-authorization in certain parts of the world. This meeting report summarizes an EMA workshop’s discussion on the epidemiology, clinical presentation and biology of thrombosis with thrombocytopenia syndrome after adenovirus vector COVID-19 vaccination. General agreement was reached by international regulators, scientists and developers on the steps needed to fill the gaps in the characterization of this new syndrome. In particular, actions should be taken to improve the post-vaccination surveillance activities in low and middle income countries and investigate potential genetic predisposition factors

Time lost due to an attack - a novel patient-reported outcome measure for acute migraine treatments

OBJECTIVE We propose a new outcome measure to assess the efficacy of migraine treatments translating the approach of the Global Burden of Disease studies from a societal to an individual level: Instead of calculating "years lived with disability", we suggest estimating "time lost due to an attack". METHODS Time lost due to an attack is calculated by multiplying the duration and the degree of impaired functioning during an attack. RESULTS Time lost due to an attack, different from other outcome measures, does not just focus on the short-term analgesic effects of treatments, but rather on the improvement of all migraine symptoms and restoration of functioning, also considering therapy-related impairment. Importantly, time lost due to an attack measures the entire time patients are not functioning normally, from onset to complete resolution. CONCLUSIONS Time lost due to an attack represents a new paradigm to assess migraine burden in single patients for a patient-centered evaluation of both acute and prophylactic treatments